Lumeda Reports Progress In Clinical Evaluation Of Its Intraoperative Photodynamic Therapy
Summary
"We have the potential to significantly reduce the incidence of recurrence with minimal side effects in patients undergoing surgery for colon and rectal cancers." PDT represents a highly promising option for adjuvant therapy administered intraoperatively with no systemic toxicities and minimal side effects. The collaboration between Roswell Park and Lumeda is accelerating the advancement of PDT from research to commercialization to expand its clinical utilization. The company applies advanced photonics and proprietary artificial intelligence (AI) software to automate and digitize PDT light delivery to improve physician control, reduce procedure time and enable data capture for treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with expertise in systems engineering and commercialization of new technology.